RESUMO
INTRODUCTION
Growing costs in health care are an important issue to be consi dered in public health. Among health technology assessment diffe rent types of studies, costeffectiveness and costutility analysis are useful tools to compare both costs and results (measured as effecti veness or as quality of life, respectively) for different interventions (1 3) . New treatment modalities need to be evaluated; in order to help decision makers to better allocate health resources (1) . Economic impact of most prevalent eye diseases and their treat ment is felt heavily on health services due especially to glaucoma, one of the leading causes of irreversible blindness in the world (4) . The re is a trend of increasing costs in the future, as both incidence and prevalence of glaucoma are expected to be higher in the next years (5) .
Glaucoma direct costs have a major impact on health care, be cause it includes: chronic use of medications, surgical procedures, medical visits and frequent exams (6) . Glaucoma chargers are respon sible for up to 12% of all medical expenses in glaucoma patients (7) . Medica tions contribute with a significant proportion of glaucoma re lated direct costs (6) . Rylander and Vold estimated the annual costs with a single medication in the United States. It varied from US$ 150.81 to US$ 873.98 (8) . If a patient needs more than one medication, which is not unusual (9, 10) , these costs are even higher. The usual care in glaucoma is to initiate treatment with one medi cation (monotherapy) (11) . If the target intraocular pressure (IOP) is not reached, a second and, not rarely, a third medication are added (911) . Once the patient is already in a threedrug regimen (maximum me Cost-effectiveness comparison between non-penetrating deep sclerectomy and maximum-tolerated medical therapy for glaucoma within the Brazilian National Health System (SUS)
Comparação de custo-efetividade entre a esclerectomia profunda não penetrante e a terapia clínica máxima tolerada para o glaucoma no Sistema Único de Saúde (SUS) dical therapy) and glaucoma is still progressing, it is usually the time for surgery (11) . However, many patients and, even their doctors, some times refuse to accept or indicate the surgical procedure due to some surgeryrelated potential risks. Therefore, many patients are kept under maximum medical therapy for a long period of time, leading to problems related to chronic use of medications, such as: ocular surface toxicity, costs, adherence, persistence and quality of life (12) . Nonpenetrating deep sclerectomy (NPDS) is a filtering glauco ma procedure, which is an alternative to trabeculectomy in patients with openangle glaucoma (13, 14) . Many studies proved its efficacy and safety and it has been recently introduced in the glaucoma surgical management in Brazil (1417) . The aim of this study is to assess the costeffectiveness of NPDS in a group of patients and to compare it to maximum medical therapy in a 5year followup.
METHODS
A decision model was built in order to allow the comparison bet ween the surgery group and the medication group ( Figure 1) .
The surgical arm of the decision analysis tree was observational and its data was derived from a retrospective chart review of conse cutive cases submitted to NPDS in the same setting (Juiz de Fora MG, Brazil), by the same surgical team, from 1999 to 2007. NPDS technique was described elsewhere (14) . Inclusion criteria were: diagnosis of pri mary openangle glaucoma under maximum medical therapy and at least 5 years of followup after surgery. If both eyes of a patient were eligible, the authors chose the first operated eye for study. Exclusion criteria were: other types of glaucoma and cataract surgery in the 5years of followup.
NPDS direct costs were based on the following variables:
• Price of NPDS paid by the Brazilian Public National Health System (SUS) using the code 04.05.05.0321 (Glaucoma Filtering Sur gery). Prices were obtained through the internet in the SIGTAP Total NPDS direct cost (in 5 years) was divided by the total num ber of eyes to find the direct cost per eye. In order to allow the com parison with medications, which are used in both eyes of the same patient, we divided the total cost of medications by two. So we could compare the costs per treated eye and not per patient.
Effectiveness was defined as the mean percentage of intraocular pressure (IOP) reduction from the preoperative period to the end of followup and was calculated as follows: [(mean baseline IOP mean final IOP)/mean baseline IOP] x 100.
In order to evaluate the NPDS ability to control IOP and allow comparisons to literature, we also calculated different NPDS success rates: IOP <21 mmHg without medication; IOP <18 mmHg without medication and IOP <18 mmHg with or without medication. Any intra and postoperative difficulties or complications were registered.
Although the patients included in this study were under maxi mum medical therapy (fixed combination of timolol/dorzolamide and a prostaglandin), their 5year cost estimation was hypothetical. We assumed the hypothesis that those patients were kept under me dication for the whole followup period (5 years) and projected the costs and effectiveness. The medications used as maximum medical therapy in this study were: fixed combination of timolol/dorzolamide (FCTD) associated with a prostaglandin analogue (bimatoprost or latanoprost or travoprost).
We used the average wholesale price (AWP) for the medications costs and their effectiveness was based on the literature. For the pros taglandin analogues effectiveness (mean percentage of IOP re duction), we chose to use Aptel et al. study (19) . They performed a metaanalysis of randomized controlled trials involving prostaglan din analogues. We decided to use peak values (higher percentage POAG= primary open-angle glaucoma; FCTD= fixed combination of 0.5% timolol maleate/2% dorzolamide; NPDS= non penetrating deep sclerectomy of IOP reduction) for effectiveness. For the additive effect of FCTD over the prostaglandin analogue, only two studies were found in the literature and all of them evaluated the IOP reduction effect of FCTD added to latanoprost (20, 21) . We assumed the same effect for the other two prostaglandin analogues (bimatoprost and travoprost). Between those two studies, we chose to use Hatanaka et al. study (21) , because of the more appropriate methodology and because it was made in a Brazilian population.
All prices were obtained in January 2010 in "reais" (Brazil's cur rency). The authors converted the "reais" values into US dollar values using January 22 nd 2010 as reference (1 dollar = 1.82 "reais"). Costeffectiveness of each decision tree arm was calculated through the division of direct cost/eye by the mean percentage of IOP reduction and was defined as the cost for each percentage of IOP reduction over 5 years.
We calculated the incremental cost, incremental effectiveness and the incremental costeffectiveness ratio (ICER).
We used a 3% discount rate. Univariate sensitivity analysis was performed using IOP reduction trough (lower percentage of IOP reduction) values as prostaglandin analogues effectiveness and different discount rates (0%; 5% and 10%).
All statistical analysis were performed using SPSS 13 (SPSS Inc., Chicago, Illinois) and Microsoft Excel (Microsoft Inc., 2007).
The Ethics Committee of the Federal University of Juiz de Fora approved this study.
RESULTS
Twohundred twentyeight eyes met the inclusion criteria, but 57 were excluded due to missing data in their charts. One hundred seventyone eyes were evaluated in the observational arm of the decision analysis tree. Table 1 shows the demographics of the studied population. NPDS direct costs and resources used are demonstrated in table 2.
In the NPDS arm, mean preoperative IOP was 24.28 mmHg and mean final IOP was 12.95 mmHg (p<0.001; Paired Student T Test). Mean percentage of IOP reduction was 46.66% from baseline to the end of followup. Success rates were: 70.76% (IOP <21 mmHg without medication); 68.42% (IOP <18 mmHg without medication); and 90.64% (IOP <18 mmHg with or without medication). Intraope rative complications were few: conversion to trabeculectomy (4.7%) and microperforations (14%). Postoperative complication rates were also low: hyphema (0.06%); choroidal detachment (0.06%); shallow anterior chamber (1.8%); bleb leaks (3.5%); bleb fibrosis (19.3%).
In the maximum medical therapy arm, costs are displayed in table 3 and mean percentage of IOP reduction varied from 26.98% (8PM) to 33.08% (8AM) for bimatoprost; from 24.49% (8PM) to 33.46% (8AM) for latanoprost and from 26.52% (4PM) to 30.98% (8AM) for tra voprost. Peak values used for costeffectiveness analysis were those from 8AM and trough values used for sensitivity analysis were those from 8PM for bimatoprost and latanoprost and 4PM for travoprost. Additive effect of FCTD found in the literature was 8.7%.
Costeffectiveness results, incremental cost and incremental ef fec tiveness are displayed in table 4. NPDS was both less costly and more effective than maximum medical therapy; therefore it was dominant.
Sensitivity analysis using trough values for IOP reduction effect did not show any differences and NPDS still remained dominant over the other treatment options. Results were not interfered by different discount rates (0%; 5% and 10%).
DISCUSSION
Our results show that NPDS demonstrated a better costeffec tiveness ratio, compared to maximum medical therapy and it was dominant over all the studied treatment options. NPDS presented the lowest direct cost for each percentage of IOP reduction in 5 years (costeffectiveness ratio).
Taking into consideration the assumptions of our study and from the Brazilian public health care provider perspective, surgery (NPDS) is the most costeffective treatment option in patients under maximum medical therapy for glaucoma over a 5year period. These results should not be different for another surgical option, trabecu lectomy, as literature has shown similar longterm results for both techniques (1317) . The main differences between these two techniques are early postoperative comfort and number of complications. Tra beculectomy patients face more complications in that period than NPDS patients (1317) . Costs for both techniques should not be very different, but it is a matter for further investigation.
We chose to use the mean percentage of IOP reduction as our effectiveness outcome measure, in order to make comparisons with medications easier. NPDS had the highest percentage of IOP re duction over 5 years (46.66%) and medications varied from 39.68% (FCTD and travoprost) to 42.16% (FCTD and latanoprost). Differences among medical therapies effectiveness values are not clinically sig nificant. NPDS effectiveness is in agreement with the literature for any glaucoma filtering procedure (both NPDS and trabeculectomy). Results in the literature show an IOP reduction between 44% and 47% for NPDS (1317) . Lichter et al. found values between 45% and 48% in the CIGTS (Collaborative Initial Glaucoma Treatment Study) for the trabeculectomy group (10) . Despite very similar effectiveness results for the three medical the rapies (39.68%; 41.78% and 42.16%), in our costeffectiveness analysis, some differences appear among them, mainly because their costs are not the same. Our results show that the most effective me dical treatment (FCTD + latanoprost) is not the most costeffective. (15) . Hondur et al. found a success rate of 67.1% for NPDS with antimetabolite (16) . Our study showed a success rate (IOP < 21 mmHg without medication) slightly above those found in the literature (70.76%), but within the limits for the 95% CI found by Cheng et al. (15) . The majority of our cases (84.8%) had moderate to advanced visual field loss. According to the Advanced Glaucoma Intervention Study (AGIS) (23) , these kinds of patients need target pressures below 18 mmHg in all measures, with a mean IOP close to 12.3 mmHg to avoid progression. At the end of followup (5 years), IOP <18 mmHg without any medication, and withorwithout medication was achie ved in 68.42% and 90.64% of studied eyes, respectively. The mean IOP after 5 years of surgery was 12.95 mmHg, reaffirming NPDS' ability to achieve target IOP in the great majority of eyes.
Intra and postoperative complications rates were similar to other published studies (1317) . The most frequent complication was filtering bleb fibrosis (19.3%) . This explains the number of 5FU injections (51 injections) and reoperations (42/171). All eyes submitted to a second NPDS were well controlled up to 5 years of followup.
The authors did not take into consideration persistence and adhe rence to medical therapy, as medications evaluations were hypothe tical. These can influence our results, as the duration of the bottle can vary according to those parameters.
Another limitation is that medication prices were based on the average wholesale price. Health care providers usually buy a large quantity of bottles, thereby receiving discounts and minimizing costs. Accordingly, an individual can benefit from pharmacy dis counts.
NPDS direct cost calculation excluded medical visits and exams. This can limit our findings, as an operated patient tends to need more visits than a patient under medical therapy. From the health care provider (payer) perspective, this influence is minimized as most of postoperative visits occur within the first month, when costs are still included in the surgical procedure charges. An increase in indirect costs (absence from work) is expected to happen and needs to be investigated. The eyes submitted to NPDS were in different glauco ma stages, which can influence the amount of resources used (5FU needling, medications, etc) and, therefore, their costs in the posto perative period. We speculate that more advanced glaucomas tend to need more resources and generate more costs than early ones. However, we chose to use all glaucoma stages in order to simulate the "real world" where indication of surgery can occur in both early and advanced glaucomas.
We also excluded from our analysis the need for cataract surgery in both arms (surgical and medical therapy). Cataract formation or progression is an important issue to consider after trabeculectomy, but not after NPDS. The majority of authors believe that NPDS does not interfere with cataract formation or progression (13) . We chose not to include cataract surgery on our analysis to keep our model as simple as possible and to avoid any influence of the cataract surgery on patient's IOP.
The most costeffective medication is not always the best the rapy. The most costeffective prostaglandin analogue in every study was bimatoprost, which is known however to have poor persisten ce (2427) . Surgical complications can also have a negative impact on patient's perceived quality of life. Incorporating quality of life as an effectiveness outcome measure would be useful and a costutility analysis on that matter would be interesting. Therefore, it is important to consider our results in a societal and collective perspective and applicable only for patients covered by the Brazilian public health service (SUS). Supplementary or private health services practice other prices and in these realities, our results could be entirely different. Adaptations must be done on an individual basis.
In our study, taking into consideration all assumptions and limi tations, NPDS was both less costly and more effective than maximum medical therapy. From the Brazilian public health service (SUS) pers pective, NPDS was the most costeffective treatment option when compared to maximum medical therapy (FCTD and prostaglandin) over a 5year period.
